174 related articles for article (PubMed ID: 35043768)
1. Role of KSP Inhibitors as Anti-cancer Therapeutics: An Update.
Chamariya R; Suvarna V
Anticancer Agents Med Chem; 2022; 22(14):2517-2538. PubMed ID: 35043768
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel spiro 1,3,4-thiadiazolines as potent, orally bioavailable and brain penetrant KSP inhibitors.
Mansoor UF; Angeles AR; Dai C; Yang L; Vitharana D; Basso AD; Gray K; Tang H; Liu M; Liang L; Allbritton O; Siddiqui MA
Bioorg Med Chem; 2015 May; 23(10):2424-34. PubMed ID: 25868746
[TBL] [Abstract][Full Text] [Related]
3. Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxane-refractory cancer: MK-0731 and analogs.
Cox CD; Garbaccio RM
Anticancer Agents Med Chem; 2010 Nov; 10(9):697-712. PubMed ID: 21235439
[TBL] [Abstract][Full Text] [Related]
4. KSP inhibitors as antimitotic agents.
Pérez-Melero C
Curr Top Med Chem; 2014; 14(20):2286-311. PubMed ID: 25434354
[TBL] [Abstract][Full Text] [Related]
5. Progress on kinesin spindle protein inhibitors as anti-cancer agents.
Zhang Y; Xu W
Anticancer Agents Med Chem; 2008 Aug; 8(6):698-704. PubMed ID: 18690830
[TBL] [Abstract][Full Text] [Related]
6. Kinesin spindle protein inhibitors in cancer: from high throughput screening to novel therapeutic strategies.
Shahin R; Aljamal S
Future Sci OA; 2022 Mar; 8(3):FSO778. PubMed ID: 35251692
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of a kinesin inhibitor.
Sakowicz R; Finer JT; Beraud C; Crompton A; Lewis E; Fritsch A; Lee Y; Mak J; Moody R; Turincio R; Chabala JC; Gonzales P; Roth S; Weitman S; Wood KW
Cancer Res; 2004 May; 64(9):3276-80. PubMed ID: 15126370
[TBL] [Abstract][Full Text] [Related]
8. Recent findings and future directions for interpolar mitotic kinesin inhibitors in cancer therapy.
Myers SM; Collins I
Future Med Chem; 2016; 8(4):463-89. PubMed ID: 26976726
[TBL] [Abstract][Full Text] [Related]
9. Recent progress in the identification and clinical evaluation of inhibitors of the mitotic kinesin KSP.
Knight SD; Parrish CA
Curr Top Med Chem; 2008; 8(10):888-904. PubMed ID: 18673173
[TBL] [Abstract][Full Text] [Related]
10. Ligand- and structure-based in silico studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents.
Balakumar C; Ramesh M; Tham CL; Khathi SP; Kozielski F; Srinivasulu C; Hampannavar GA; Sayyad N; Soliman ME; Karpoormath R
J Biomol Struct Dyn; 2018 Nov; 36(14):3687-3704. PubMed ID: 29064326
[TBL] [Abstract][Full Text] [Related]
11. Kinesin spindle protein (KSP) inhibitors in combination with chemotherapeutic agents for cancer therapy.
Song H; Zhou S; Wang R; Li S
ChemMedChem; 2013 Nov; 8(11):1736-49. PubMed ID: 23964020
[TBL] [Abstract][Full Text] [Related]
12. The Application of Kinesin Inhibitors in Medical Issues.
Nejabat M; Hadizadeh F; Sahebkar A
Curr Rev Clin Exp Pharmacol; 2024 Jan; ():. PubMed ID: 38275041
[TBL] [Abstract][Full Text] [Related]
13. Conformation-dependent ligand regulation of ATP hydrolysis by human KSP: activation of basal hydrolysis and inhibition of microtubule-stimulated hydrolysis by a single, small molecule modulator.
Luo L; Carson JD; Molnar KS; Tuske SJ; Coales SJ; Hamuro Y; Sung CM; Sudakin V; Auger KR; Dhanak D; Jackson JR; Huang PS; Tummino PJ; Copeland RA
J Am Chem Soc; 2008 Jun; 130(24):7584-91. PubMed ID: 18491908
[TBL] [Abstract][Full Text] [Related]
14. Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance.
Garcia-Saez I; Skoufias DA
Biochem Pharmacol; 2021 Feb; 184():114364. PubMed ID: 33310050
[TBL] [Abstract][Full Text] [Related]
15. Mitotic kinesins: prospects for antimitotic drug discovery.
Bergnes G; Brejc K; Belmont L
Curr Top Med Chem; 2005; 5(2):127-45. PubMed ID: 15853642
[TBL] [Abstract][Full Text] [Related]
16. Developments of kinesin spindle protein inhibitors as antitumor agents based on the five-membered heterocycle scaffolds.
Zhao GD; Wan RZ; Liu ZP
Curr Med Chem; 2014; 21(23):2691-701. PubMed ID: 24606497
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of inhibition of human KSP by ispinesib.
Lad L; Luo L; Carson JD; Wood KW; Hartman JJ; Copeland RA; Sakowicz R
Biochemistry; 2008 Mar; 47(11):3576-85. PubMed ID: 18290633
[TBL] [Abstract][Full Text] [Related]
18. Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others.
Warner SL; Gray PJ; Von Hoff DD
Semin Oncol; 2006 Aug; 33(4):436-48. PubMed ID: 16890798
[TBL] [Abstract][Full Text] [Related]
19. ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism.
Luo L; Parrish CA; Nevins N; McNulty DE; Chaudhari AM; Carson JD; Sudakin V; Shaw AN; Lehr R; Zhao H; Sweitzer S; Lad L; Wood KW; Sakowicz R; Annan RS; Huang PS; Jackson JR; Dhanak D; Copeland RA; Auger KR
Nat Chem Biol; 2007 Nov; 3(11):722-6. PubMed ID: 17922005
[TBL] [Abstract][Full Text] [Related]
20. Kinesin-5: cross-bridging mechanism to targeted clinical therapy.
Wojcik EJ; Buckley RS; Richard J; Liu L; Huckaba TM; Kim S
Gene; 2013 Dec; 531(2):133-49. PubMed ID: 23954229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
